Condensed Consolidated Interim Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2020 and 2019 (Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that the condensed consolidated interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The unaudited condensed consolidated interim financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards for the preparation of unaudited condensed consolidated interim financial statements and are in accordance with International Accounting Standard 34 - Interim Financial Reporting.

The Company's independent auditor has not performed a review of these unaudited condensed consolidated interim financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

TABLE OF CONTENTS

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION	3
CONDENSED CONSOLIDATED INTERIM STATEMENT OF OPERATIONS	4
CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY	5
CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOW	6
NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN	7
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	7
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED	8
NOTE 3 – SALE OF CANADIAN OPERATING ASSETS	8
NOTE 4 – LOSS ON WRITE-DOWN OF ASSETS	8
NOTE 5 – CCAA SETTLEMENT	8
NOTE 5 – CCAA SETTLEMENT, CONTINUED	9
NOTE 6 – TRADE AND OTHER RECEIVABLES	9
NOTE 7 – PREPAID EXPENSES	9
NOTE 8 – INVESTMENTS	10
NOTE 9 – PROPERTY, PLANT AND EQUIPMENT	10
NOTE 9 – PROPERTY, PLANT AND EQUIPMENT, CONTINUED	
NOTE 10 – INTANGIBLE ASSETS	
NOTE 11 – LOAN RECEIVABLE	13
NOTE 12 – OBLIGATIONS UNDER RIGHT-OF-USE LEASE	13
NOTE 13 – SHORT TERM DEBT PAYABLE	13
NOTE 14 – CONVERTIBLE DEBENTURE AND LONG-TERM LIABILITIES	13
NOTE 15 – SHARE CAPITAL	14
NOTE 16 – SHARE PURCHASE WARRANTS	
NOTE 17 – SHARE-BASED COMPENSATION	
NOTE 18 – SUPPLEMENTAL CASH FLOW INFORMATION	16
NOTE 19 – SEGMENTED INFORMATION	
NOTE 19 – SEGMENTED INFORMATION, CONTINUED	17
NOTE 20 – RELATED PARTY TRANSACTIONS	17
NOTE 21 – CAPITAL MANAGEMENT	17
NOTE 21 – CAPITAL MANAGEMENT, CONTINUED	18
NOTE 22 – FINANCIAL INSTRUMENTS	18
NOTE 23 - RECLASSIFICATION OF PRIOR PERIOD PRESENTATION	20
NOTE 24 – SUBSEQUENT EVENTS	20

LUFF ENTERPRISES LTD. (FORMERLY ASCENT INDUSTIRES CORP.) CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

(Expressed in Canadian Dollars) As at September 30, 2020 and December 31, 2019

	September	September 30, 2020			
Assets					
Current assets:					
Cash and cash equivalents	\$	645,846	\$	3,993,021	
Trade and other receivables (Note 6)	-	787,898		746,877	
Prepaid expenses (Note 7)		82,149		72,030	
Investments (Note 8)	4	408,204		376,502	
Inventory		84,680		-	
	2,0	008,777		5,188,430	
Long-term assets					
Property held for sale (Note 9)		967,761			
Property, plant & equipment, net (Note 9)		333,386		7,368,860	
Intangible assets (Note 10)	·	047,923		1,056,087	
Note receivable (Note 11)	7	727,925		-	
Right of use asset (Note 12)	-	<u>-</u>		52,020	
	\$ 10,5	585,772	\$	13,665,397	
Liabilities and sharesholders' equity					
Current liabilities					
Accounts payable, payroll and accrued liabilities	\$	170,453	\$	413,888	
Long-term liabilities					
Right of use lease (Note 12)		-		49,479	
Loans payable (Note 14)		425,458		-	
	ţ	595,911		463,367	
Shareholders' equity					
Share capital (Note 15)	72,0	035,644		70,513,445	
Contributed surplus	1,7	734,012		1,572,639	
Share based reserve (Note 17)	1,2	241,312		1,241,312	
Accumulated other comprehensive income	(2	278,462)		(311,456)	
Deficit	(64,	742,645)		(59,813,910)	
Total equity	9,9	989,861		13,202,030	
Total liabilities and equity	\$ 10,5	585,772	\$	13,665,397	

LUFF ENTERPRISES LTD. (FORMERLY ASCENT INDUSTIRES CORP.) CONDENSED CONSOLIDATED INTERIM STATEMENT OF OPERATIONS

(Expressed in Canadian Dollars)

Three and Nine Months Ended September 30, 2020 and September 30, 2019

	3 Months ember 30, 2020	Sept	3 Months tember 30, 2019	Sept	9 Months ember 30, 2020		9 Months emer 30, 2019
Revenue:		Φ.	co 200	Φ.	5.040	•	070.050
Sales Cost of sales	- 4,927	\$	62,296 (89,517)	\$	5,019 11,592	\$	679,852 1,079,064
Gross margin	 (4,927)		151,813		(6,573)		(399,212)
Expenses:							
General and administration	145,042		1,818,371		2,884,612		6,215,139
Selling and marketing	107,184		23,922		124,702		542,769
Research & development	-		12,773		-		184,102
Depreciation & amortization	 203,765		202,247		609,005		606,741
	 455,991		2,057,313		3,618,319		7,548,751
Loss from operations	 (460,918)		(1,905,500)		(3,624,892)		(7,947,963)
Other (income) expenses							
Interest and other	(78,703)		529,822		1,409		2,144,493
Share issuance cost	(4,561)		-		156,812		-
Gain on sale	(10,657)		-		(10,657)		(2,915,810)
Loss on disposal	-		-		-		132,891
CCAA Settlement	-		-		889,309		1,200,000
Unrealized gain on investments	(15,702)		-		(31,702)		-
Bad debt expense	-		-		285,512		-
Accretion expense	 1,882		<u>-</u>		10,034		-
	 (107,741)		529,822		1,300,717		561,574
Loss Before Income Taxes and Comprehensive Income	(353,177)		(2,435,322)		(4,925,609)		(8,509,537)
Income tax expense	 629		1,124		3,126		13,519
Net Loss	(353,806)		(2,436,446)		(4,928,735)		(8,523,056)
Comprehensive Income							
Currency translation adjustment	 (496,272)		(4,147)		32,994		(762,434)
Comprehensive Loss	\$ (849,449)	\$	(2,440,593)	\$	(4,895,741)	\$	(9,285,490)
Basic and diluted loss per share	\$ (0.00)	\$	(0.01)	\$	(0.01)	\$	(0.03)
Weighted average number of							
common shares outstanding, diluted	 390,083,032		320,151,457		390,083,032		320,151,457

LUFF ENTERPRISES LTD. (FORMERLY ASCENT INDUSTRIES CORP.)

Condensed Interim Consolidated Statement of Changes in Shareholders' Equity

(Expressed in Canadian Dollars)

Nine Months Ended September 30, 2020 and Periods Ended December 31, 2019 and 2018

	Common Number	Shares \$	Common shares to be issued \$	Share-based reserve	Warrant reserve	Contributed Surplus \$	Accumulated other comprehensive loss	Deficit \$	Shareholders' Equity \$
As at June 1, 2018	218,683,015	31,576,460	8,673,862	507, 151	-	1,572,639	23,671	(20,299,670)	22,054,113
Exercise of warrants (for private placement A)	-	916,667	-	-	-	-	-	-	916,667
Exercise of warrants (for private placement B)	3,666,666	-	-	-	-	-	-	-	-
Units issued as a deposit	2,777,778	-	-	-	-	-	-	-	-
Shares issued as a deposit	416,667	1,150,000	-	-	-	-	-	-	1,150,000
Units issued for services	205,556	-	_	-	_	-	-	-	-
Shares issued for services	458,810	271,200	-	-	-	-	-	-	271,200
Shares issued for equipment	1,412,152	621,647	-	-	-	-	-	_	621,647
Shares issued through First Circle acquisition	562,500	225,000	250,000	-	-	-	_	_	475,000
Units issued for private placement D	30,000,000	12,000,000	(8,673,862)	-	_	_	_	_	3,326,138
Units issued for finders fees	510,407	204, 163	-	-	_	_	_	_	204, 163
Units issued through public offering	48,085,500	19,234,200	_	-	_	_	_	_	19,234,200
Units issued through Paget Mineral acquisition	9,542,643	3,796,748	_	_	_	_	_	_	3,796,748
Exercise of warrants (for private placement D)	3,829,763	1,970,232	298,597	_	_	_	_	_	2,268,829
Share issuance costs	-	(1,751,469)	200,007	_	_	_	_	_	(1,751,469
Share based compensation	_	(1,101,100)	_	734, 161	_	_	_	_	734, 161
Foreign currency reserve	_	_	_	704,101	_	_	(220,978)	_	(220,978
Net loss for the period	-	-	-	-	-	-	-	(17, 367, 855)	(17,367,855
As at December 31, 2018	320, 151, 457	70,214,848	548,597	1,241,312	-	1,572,639	(197,307)	(37,667,525)	35,712,564
Shares issued	-	298,597	(298, 597)	-	-	-	-	-	-
Shares written off	-	-	(250,000)	-	-	-	-	250,000	-
Foreign currency reserve	-	-	-	-	-	-	(114, 149)	-	(114, 149
Net loss for the period	-	-	-	-	-	-	-	(22, 396, 385)	(22, 396, 385
As at December 31, 2019	320,151,457	70,513,445	-	1,241,312	-	1,572,639	(311,456)	(59,813,910)	13,202,030
Shares issued for services	7,200,000	180,000	-	-	-	_	-	-	180,000
Shares issued for debt	35,572,372	889,309	-	-	-	-	-	-	889,309
Shares issued in private placement	27, 159, 203	434,875	-	-	-	-	-	-	434,875
Warrants issued	-	-	-	-	-	161,373	-	-	161,373
Convertible debenture	-	22,576	-	-	-	-	-	-	22,576
Share issuance costs	-	(4,561)	-	-	-	-		-	(4,561
Foreign currency reserve	-	-	-	-	-	-	32,994	-	32,994
Net loss for the period	-	-	-	-	-	-	-	(4,928,735)	(4,928,735
Balance, September 30, 2020	390,083,032	\$ 72,035,644	\$ -	\$ 1,241,312	\$ -	\$ 1,734,012	\$ (278,462)	\$ (64,742,645)	\$ 9,989,861

LUFF ENTERPRISES LTD. (FORMERLY ASCENT INDUSTIRES CORP.) CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOW

(Expressed in Canadian Dollars) Nine Months Ended September 30, 2020 and 2019

	9 months ended September 30, 2020	9 months ended September 30, 2019		
Cash provided by (used for):				
Operating activities:				
Net Loss for the period	\$ (4,928,735)	\$ (8,523,056)		
Items not affecting cash:				
Depreciation & amortization	609,005	606,741		
Accretion expense	10,034	-		
Gain on sale of assets	-	(2,915,810)		
Warrants issued	161,373	-		
Shares issued for services	180,000	-		
Debenture	438,000	-		
CCAA Settlement	889,266	1,200,000		
Unrealized gain on investments	(15,702)	-		
(Gain) Loss on disposal	-	132,891		
Accumulated other comprehensive gain	-	343,110		
Changes in non-cash working capital balances:				
Receivables	393,907	18,371,908		
Prepaid expenses	(8,162)	73,835		
Inventory	(84,566)	1,413,219		
Commission payable	<u>-</u>	978,840		
Accounts payable, payroll and accrued liabilities	(43,503)	(153,949)		
Cash used by operating activities	(2,399,084)	11,527,729		
Investing activities:				
Purchase property, plant and equipment	(28,106)	-		
Proceeds of intangible assets	· -	3,128,427		
Purchase of investments	(16,000)	-		
Note receivable, related party	(727,925)			
Cash provided (used) by investing activities	(772,031)	3,128,427		
Financing activities:				
Units & shares issued	434,875	_		
Change in right of use asset	· -	-		
Advances from related parties	(421,060)	-		
Cash used by financing activities	13,815			
Increase (Decrease) in cash and cash equivalents	(3,157,300)	14,656,156		
	,			
Effect of exchange rate changes on cash	(189,875)	(1,093,255)		
Cash and cash equivalents, beginning of period	3,993,021	1,339,027		
Cash and cash equivalents, end of period	\$ 645,846	\$ 14,901,928		

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 1 – Nature of Operations and Going Concern

The Company was incorporated under the Business Corporations Act (British Columbia) on May 30, 2013 under the name Ascent Industries Corp. ("Ascent"). On May 15, 2020 the Company changed its name to LUFF ENTERPRISES LTD. ("Luff"). The Company's head office and principal address is located at Suite 800 – 543 Granville Street, Vancouver, BC V6C 1X8.

The condensed consolidated interim financial statements as at and for the three and nine months ended September 30, 2020 should be read in conjunction with the consolidated financial statements for the year ended December 31, 2019.

The Company's primary activities relate to the production of cannabinoid consumer packaged goods using THC free product. The Company holds licenses for cannabis processing, production, research, product and brand development, and distribution that could be used in the future.

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis which assumes that the Company will continue to operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. In the nine months ended September 30, 2020 the Company has generated \$5,019 in revenues from operations and incurred a net loss of \$(4,928,735). As of September 30, 2020, the Company had an accumulated deficit of \$64,742,645.

In the year ended December 31, 2019, the Company defaulted on certain debts and failed to secure proper licensing in Canada to produce and sell cannabis and cannabis related products. These events substantially restricted access to continue operations and, as a result, the Company filed for protection under the Companies' Creditors Arrangement Act (the "CCAA"). Effective May 26, 2020 the Company was discharged from this process, having settled with all claimants.

The Company through its subsidiaries owns the assets related to hemp cultivation, production, distribution, research and product development business outside of Canada in Oregon and Nevada. On March 14, 2019 the Company, together with its subsidiaries Agrima Botanicals Corp., Bloom Holdings Ltd., Bloom Meadows Corp., Pinecone Products Ltd., and Agrima Scientific Corp. (collectively, the "Vendors") sold substantially all of the assets comprising the Canadian business of the Vendors for cash and the assumption of debts related to the sold assets including a greenhouse located in Pitt Meadows, British Columbia.

The Company has historically financed its working capital requirements primarily through equity and debt financing. The Company's ability to continue as a going concern is dependent upon its ability to commence profitable operations in Oregon and generate funds therefrom or raise additional financing in order to meet current and future obligations. While the Company has been successful in raising financing in the past, there is no assurance that it will be able to obtain additional financing or that such financing will be available on reasonable terms once it leaves CCAA protection. These conditions combined with the accumulated losses to date indicate the existence of a material uncertainty that may cast doubt on the Company's ability to continue as a going concern.

These condensed consolidated interim financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 – Summary of Significant Accounting Policies

a) Statement of compliance and basis of presentation

These condensed consolidated interim financial statements for the three and nine months ended September 30, 2020 have been prepared in accordance with International Accounting Standard ("IAS") 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). The condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the annual financial statements for the year ended December 31, 2019, which have been prepared in accordance with IFRS, as issued by the IASB.

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 2 – Summary of Significant Accounting Policies, continued

Statement of compliance and basis of presentation, continued

The condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 17, 2020.

These condensed consolidated interim financial statements follow the same accounting policies and methods of application as the consolidated financial statements as at and for the year ended December 31, 2019.

b) Basis of consolidation

These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Agrima Botanicals Corp., Bloom Holdings Ltd., Bloom Meadows Corp., Pinecone Products Ltd., Agrima Scientific Corp., Azeha Holdings Ltd., Agrima Botanicals ApS (Denmark), West Fork Holdings Inc., West Fork Holdings NV Inc., Sweet Cannabis Inc., Luff Enterprises LLC., Sweet Cannabis NV Inc., Luff Enterprises NV Inc., AIC Health Winnipeg Corp., AIC Health Winnipeg Wellness Corp., and AIC Health Services Corp. All significant inter- company balances and transactions have been eliminated on consolidation.

Note 3 – Sale of Canadian Operating Assets

Effective April 8, 2019 and pursuant to an order issued by the Supreme Court of British Columbia on March 25, 2019, the Company sold the Pitt Meadows facility, the Maple Ridge facility and a lease contract to BZAM Management Inc. and subsequently commenced the winding up of its Canadian operations.

The consideration was allocated as follows:

Sale of Assets	
Gross Consideration	\$ 19,152,056
Less Commission	(978,840)
Inventory	(541,877)
Prepaids	(103,221)
Deposits and Construction in Progress	(14,432,232)
Property, Plant and Equipment	(10,674,398)
Assumption of Long-term Debt	8,518,259
Assumption of Derivative Debt	1,976,063
	\$ 2,915,810

Note 4 – Loss on Write-down of Assets

The Company recorded a loss on the write-down of its assets in Canada and Denmark which were deemed to have no value, in the total amount of \$5,952,843. See Note 10: Intangible Assets.

Note 5 – CCAA Settlement

On March 1, 2019, by order of the Supreme Court of British Columbia, Ascent Industries Corp. along with the wholly owned subsidiaries, Agrima Botanicals Corp., Bloom Holdings Ltd., Bloom Meadows Corp., Pinecone Products Ltd., Agrima Scientific Corp., and West Fork Holdings NV Inc. (the "Petitioners") were granted protection under CCAA from its creditors under Vancouver Registry No. S-192188. Ernst & Young Inc. was appointed as Monitor of the Petitioners.

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 5 - CCAA Settlement, continued

The allowable claims were segregated into two classes:

- (i) the unaffected claims: claims below \$11,100 and paid in full;
- (ii) the affected claims: claims affected by the compromise 51% of the original allowed amount paid.

In addition to the cash settlement of \$9,361,913 paid in final settlement, Company issued the affected claimants the 35,572,372 common shares with an aggregate value of \$889,309 to eligible affected shareholders on March 03, 2020.

The Company recorded a loss on its settlement with CCAA in the amount of \$5,280,251.

On March 6, 2020, the Company announced that it had implemented its first amended and restated consolidated plan of compromise, arrangement and organization (the "Plan") under the Companies' Creditors Arrangement Act ("CCAA"). Distributions under the Plan, as well as the issuance of common shares of Ascent that were to be issued pursuant to the terms of the Plan, have been completed. The stay of proceedings expired on March 6, 2020 and the Company's CCAA proceedings concluded upon expiry of the stay.

Note 6 – Trade and Other Receivables

	September 30 2020	December 31 2019
Trade receivables GST recoverable	\$ - 787,898	\$ - 746,877
	\$ 787,898	\$ 746,877

During the three and nine months ended September 30, 2020 approximately \$285,000 of GST recoverable was written off as bad debt as management deemed it uncollectible. In the year ended December 31, 2019 no bad debt expense was recognized.

Note 7 – Prepaid Expenses

	September 30 2020	December 31 2019
Prepaid vendors	\$ 22,854	\$ 14,295
Prepaid rent Deposits	- 59,295	57,735 -
	\$ 82,149	\$ 72,030

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 8 – Investments

During the year ended May 31, 2018, the Company invested in Enhanced Pet Sciences Corp., a privately held, startup company that is developing consumer packaged goods incorporating cannabinoid extracts. The Company does not have significant influence or control over the investee. The investee is privately held and there is no quoted market price for its common shares.

Through its amalgamation with Paget Minerals Corp in August 2018, the Company acquired a 1.5% royalty in the Buck claim within the Capoose block of the Blackwater Gold-Silver Project (the Project). The Company has not assigned a value to this royalty as it is not quantifiable at this time, and there is uncertainty as to the collectability of the royalty as the Project was not part of the feasibility study completed recently by the Project owner.

During the period ended December 31, 2018, the Company acquired an investment in Sebastiani Ventures Corp, a publicly traded company previously held by Paget Minerals Corp. The Company does not have significant influence or control over the investee. Also through its amalgamation with Paget Minerals, the Company acquired the right to future payments, either in cash or shares, from Evrim Resources (Evrim), of third party and/or joint venture projects related to the Ball Creek Project. Evrim entered into a joint venture project with Golden Ridge Resources, Ltd., in 2019, and thus the Company received 380,000 shares in Golden Ridge Resources Ltd., pursuant to the agreement. The shares are valued at the quoted market price in the condensed consolidated interim statement of financial position.

	September 30 2020	December 31 2019
Enhanced Pet Sciences Corp. Sebastiani Ventures Corp. Golden Ridge Resources, Ltd.	\$ 360,000 16,502 31,702	\$ 360,000 16,502 -
	\$ 408,204	\$ 376,502

Note 9 – Property, Plant and Equipment

Cost	_	December 31 2019	 Additions	 Adjustments/ Transfers	_	Disposals	September 30 2020
Land	\$	667,177	\$ -	\$ (1,018)	\$	- \$	666,159
Buildings		4,308,175	-	(6,573)		-	4,301,602
Computer equipment		71,211	3,157	(230)		-	74,138
Software		7,157	-	(11)		-	7,146
Mobile equipment		33,000	-	(50)		-	32,950
Furniture and fixtures		52,733	-	(80)		-	52,653
Security equipment		185,642	-	(284)		-	185,358
Tools and equipment		1,114,513	-	(1,114,513)		-	-
Lab equipment		223,818	28,392	1,112,471		-	1,364,681
Leasehold improvements		2,359,348	-	(3,600)		-	2,355,748
Right of use assets		244,589	-	(244,589)		-	-
	\$	9,267,363	\$ 31,549	\$ (258,477)	\$	- \$	9,040,435

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 9 – Property, Plant and Equipment, continued

Accumulated Amortization	_	December 31 2019	-	Additions	_	Adjustments/ Transfers	_	Disposals	_	September 30 2020
Buildings	\$	(224,384)	\$	(79,629)	\$	-	\$	- \$	5	(304,013)
Computer equipment		(44,850)		(17,949)		-		-		(62,799)
Software		(3,877)		(1,770)		-		-		(5,647)
Mobile equipment		(17,875)		(6,096)		-		-		(23,971)
Furniture and fixtures		(20,191)		(4,293)		-		-		(24,484)
Security equipment		(111,119)		(43,596)		-		-		(154,715)
Tools and equipment		(570,426)		-		570,426		-		-
Lab equipment		(118,149)		(257,845)		-		-		(375,994)
Leasehold improvements		(543,044)		(174, 195)		(570,426)		-		(1,287,665)
Right of use assets	_	(192,569)	_	-	_	192,569	_		_	-
	\$_	(1,846,484)	\$	(585,373)	\$_	192,569	\$_		5 _	(2,239,288)

Cost	_	December 31 2018	_	Additions	_	Adjustments/ Transfers	_	Disposals	_	December 31 2019
Construction in progress	\$	6,361,671	\$	-	\$	-	\$	(6,361,671)	\$	_
Land		1,321,159		-		-		(653,982)		667,177
Buildings		9,416,042		-		-		(5,107,867)		4,308,175
Computer equipment		504,840		-		-		(433,629)		71,211
Wireless network		87,003		-		-		(87,003)		-
Software		42,317		-		-		(9,317)		33,000
Mobile equipment		77,815		-		-		(42,019)		35,796
Furniture and fixtures		345,705		-		-		(292,972)		52,733
Security equipment		609,038		-		-		(452,035)		157,003
Tools and equipment		2,122,614		-		-		(790,806)		1,331,808
Lab equipment		2,896,968		-		-		(2,890,445)		6,523
New groundwork		133,182		-		-		(133,182)		-
Leasehold improvements		3,835,024		-		-		(1,475,676)		2,359,348
Right of use assets	_	-	_	244,589	_	-	_	-	_	244,589
	\$_	27,753,378	\$_	244,589	\$	-	\$_	(18,730,604)	\$_	9,267,363

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 9 – Property, Plant and Equipment, continued

Accumulated Amortization	_	December 31 2018	_	Additions	-	Adjustments/ Transfers	_	Disposals	-	December 31 2019
Buildings	\$	(922,308)	\$	(137,910)	\$	-	\$	835,834	\$	(224,384)
Computer equipment		(192,991)		(30,394)		-		178,535		(44,850)
Wireless network		(87,003)		-		-		87,003		-
Software		(23,440)		(11,444)		-		17,009		(17,875)
Mobile equipment		(39,364)		(11,459)		-		39,290		(11,533)
Furniture and fixtures		(177,339)		(13,505)		-		170,653		(20,191)
Security equipment		(190,316)		(67,012)		-		153,865		(103,463)
Tools and equipment		(489,541)		(233,760)		-		38,124		(685,177)
Lab equipment		(1,415,486)		(2,088)		-		1,414,176		(3,398)
New groundwork		(68,225)		-		-		68,225		-
Leasehold improvements		(398,687)		(302, 103)		-		157,746		(543,044)
Right of use assets	_	_	_	(192,569)	_	-	_	-	_	(192,569)
	\$_	(4,004,700)	\$	(1,002,244)	\$	-	\$_	3,160,460	\$_	(1,846,484)

	S	eptember 30	December 31
Net Book Value		2020	2019
Land	\$	666,159 \$	667,177
Buildings		3,997,589	4,083,791
Computer equipment		11,339	26,361
Software		1,499	15,125
Mobile equipment		8,979	24,263
Furniture and fixtures		28,169	32,542
Security equipment		30,643	53,540
Tools and equipment		-	646,631
Lab equipment		988,687	3,126
Leasehold improvements		1,068,083	1,816,304
Right of use assets		<u> </u>	52,020
	\$	6,801,147 \$	7,420,880

Approximately \$5 million of the assets above located in the United Sates are currently shown as held for sale on the interim consolidated statement of financial position. The Company's property in Las Vegas, Nevada, is listed on the market at a selling price of \$5,500,000 USD. To date it is not in contract for purchase.

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 10 – Intangible Assets

	September 30 2020			December 31 2019	
Licenses Accumulated amortization	\$	1,121,268 (73,345)	\$	1,105,799 (49,712)	
	\$	1,047,923	\$	1,056,087	

Amortization expense of \$23,633 was recorded in the nine months ended September 30, 2020 and \$7,036 for the three months ended September 30, 2020. Amortization expense was \$14,702 in the year ended December 31, 2019.

Note 11 - Loan Receivable

On January 28, 2020 the Company entered into a secured loan agreement with Enhanced Pet Sciences Corp for US\$500,000 (CAD\$727,925). The loan bears interest at 8% per annum and is due on December 31, 2020. The principals of the borrower have provided guarantees and have provided collateral security.

Note 12 - Obligations Under Right-of-Use Lease

	September 30 2020	December 31 2019
Lease liabilities bearing interest at 5.70% per annum, due in 2020 and 2021 Amounts payable within one year	\$ - -	\$ 49,479 -
	\$ -	\$ 49,479

The lease obligation and related asset was written off in the three months ended March 31, 2020 as it was immaterial.

Note 13 – Short Term Debt Payable

A wholly owned subsidiary of the Company had a mortgage on its property in Maple Ridge, BC. The initial mortgage amount was for \$1,800,000 for a two-year period beginning January 1, 2016 bearing interest at 8.5% per annum compounded monthly. The mortgage was renewed for a one-year term on January 1, 2018 for the principal outstanding of \$1,754,546 with the same interest rate of 8.5% per annum compounded monthly, requiring monthly interest payments of \$14,494. The short-term debt payable at December 31, 2018 was \$1,731,003. The mortgage was discharged in the course of the asset sale in 2019 (Note 3).

Note 14 – Convertible Debenture and Long-Term Liabilities

Effective May 29, 2017 and as amended July 26, 2018, a wholly owned subsidiary of the Company had an 8.0% interest only mortgage on its Las Vegas, NV property. The aggregate amount of the mortgage is \$4,000,000 and was due in 2019. The mortgage was discharged during the course of the asset sale in 2019 (Note 3).

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 14 – Convertible Debenture and Long-Term Liabilities, continued

On May 28, 2020, the Company issued a three year unsecured convertible debenture having a principal amount of \$438,000 (the "Convertible Debenture") to a company controlled by a shareholder of the Company for the reimbursement of costs incurred by the shareholder in connection with the CCAA proceedings deemed of benefit and in the interest of the Company. The Convertible Debenture is convertible into 17,520,000 Common shares of the Company at the election of the shareholder, at any time and by the Company's election, during any period where the 20-day weighted average trading price of the Company's common shares is \$0.10 or greater.

The Convertible Debenture is presented on the condensed interim consolidated statement of financial position as follows:

	September	30	December 31
	2020		2019
Principal balance	\$ 425,458	\$	_
Debt discount balance	\$ 22,575	\$	-

The Convertible Debenture has been discounted to its net present value using a coupon rate of 6% and a yield rate of 8%. The debt discount is amortized over the term of the note using the effective interest rate. Accretion expense of \$1,882 and \$10,034 is included in the condensed consolidated interim statement of operations for the three and nine months ended September 30, 2020, respectively (none at December 31, 2019). The debt discount balance of \$22,575 is included in equity on the condensed interim consolidated statement of financial position.

Note 15 – Share Capital

	•	mber 30 020	December 31 2019
Issued: 390,083,032 Common Shares	\$ 72,0	35,644	\$ 70,513,445

At September 30, 2020, there were 362,923,829 issued and fully paid common shares (December 31, 2019 320,151,457).

On March 3, 2020, the Company issued 35,572,372 common shares at a price of \$0.025 per share under the Plan of Compromise, Arrangement and Reorganization (Note 5). On May 15, 2020, the Company issued 7,200,000 common shares at a price of \$.025 per share to settle professional services debts.

On September 22, 2020, the Company completed a non-brokered Private Placement issuing 27,159,103 common shares at a price of \$0.016 per share for gross proceeds of \$434,547.24. All securities issued under the Private Placement will be subject to a four month hold period expiring January 22, 2021, in accordance with applicable securities laws. Finder's fees of \$1,340 were paid in connection with the offering.

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 16 – Share Purchase Warrants

	Amount	Value per Share
Balance, May 31, 2018	12,500,000	\$ 0.250
Expired	(12,000,000)	0.250
Issued	2,885,130	0.400
Issued	33,493,741	0.500
Issued	56,581,500	0.600
Exercised	(51,796)	0.400
Exercised	(2,833,334)	5.000
Exercised	(1,796,499)	0.600
Balance, December 31, 2018	88,778,742	0.250
Expired	(350,000)	0.600
Balance, September 30, 2020 and December 31, 2019	88,428,742	\$ 0.050

During the year ended December 31, 2019, 350,000 warrants at a deemed exercise price of \$0.60 expired. On June 11, 2020, the Company issued a Supplemental Indenture whereby all outstanding warrants were repriced to a reduced exercise price of \$0.05 per warrant and an extended expiration date of June 24, 2021.

The fair value of the warrants at the date of grant was estimated to be \$161,373 based on the following weight average assumptions: stock price volatility -85%, risk free rate - .25%, dividend yield -0.00% and expected life of 12 months.

The following table summarizes the warrants that remain outstanding as at September 30, 2020:

Exercise Price	Number of Warrants	Expiry Date
\$0.05	88,428,742	June 24, 2021

Not all common shares issuable on exercise of these warrants have yet been issued, and accordingly, these have been reflected as common shares to be issued on the statement of changes of shareholders' equity.

Note 17 – Share-Based Compensation

During the year ended May 31, 2018, the shareholders of the Company approved a Stock Option Plan to attract and retain directors, employees, officers and consultants for contributions towards the long-term goals of the Company. The directors approved the continuance of this plan in June 2020 by reserving 10% of the issued and outstanding shares for stock options.

The Company recorded \$nil for the period ended December 31, 2019 (\$734,161 in the seven months ended December 31, 2018) in share-based compensation expense related to options.

In the year ended December 31, 2019, all stock options expired or were cancelled when staff was terminated.

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 18 – Supplemental Cash Flow Information

During the year ended December 31, 2019, obligation to issue shares in the First Circle Medical Pharmacy and Clinic acquisition was reversed in the amount of \$250,000; exercise of warrants related to same acquisition was reversed in the amount of \$298,597; and income taxes were paid in the amount of \$2,154.

On March 3, 2020 the Company issued 35,572,372 common shares having an inferred value of \$889,309 in relation to the final settlement of Affected Creditor claims under CCAA proceedings.

On May 15, 2020, the Company issued 7,200,000 common shares at a price of \$.025 per share to settle professional services debts.

On May 28, 2020, the Company issued a three year unsecured convertible debenture having a principal amount of \$438,000 (the "Convertible Debenture") to a company controlled by a shareholder for the reimbursement of costs incurred the shareholder in connection with the CCAA proceedings deemed of benefit and in the interest of the Company. (See Note 14).

Note 19 – Segmented Information

<u></u>		Cannabis		Other		Total
For the nine months ended September 30, 2020						
Revenue	\$	5,019	\$	-	\$	5,019
Gross profit (loss)		(6,573)		-		(6,573)
Income (loss) from operations		(3,806,762)		-		(3,806,762)
Net income (loss)		(4,928,735)		-		(4,928,735)
For the year ended December 31, 2019						
Revenue	\$	744,040	\$	-	\$	744,040
Gross profit (loss)		(1,004,928)		-		(1,004,928)
Income (loss) from operations		(10,974,818)		-		(10,974,818)
Net income (loss)		(10,974,818)		(11,421,566)		(22,396,384)
As at September 30, 2020						
Total assets	\$	10,585,772	\$	-	\$	10,585,772
Total liabilties		595,909		-		595,909
As at December 31, 2019						
Total assets	\$	8,681,590	\$	4,983,804	\$	13,665,394
Total liabilties		30,611		432,751		463,362

The Company generates revenue in two geographical locations: Canada and the USA. All revenues during the three and nine months ended September 30, 2020 and the year ended December 31, 2019 were generated in Canada and the USA and all material assets and liabilities were located in Canada and the USA.

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 19 - Segmented Information, continued

	Canada	USA	Total
For the nine months ended September 30, 2020	· ·	_	_
Revenue	\$ - \$	5,019	\$ 5,019
Gross profit (loss)	-	(6,573)	(6,573)
Income (loss) from operations	(2,295,008)	(1,511,754)	(3,806,762)
Net income (loss)	(3,592,586)	(1,336,149)	(4,928,735)
For the year ended December 31, 2019			
Revenue	\$ - \$	744,040	\$ 744,040
Gross profit (loss)	-	(1,004,928)	(1,004,928)
Income (loss) from operations	(6,894,790)	(4,080,028)	(10,974,818)
Net income (loss)	(17,628,880)	(4,767,504)	(22,396,384)
As at September 30, 2020			
Total assets	\$ 2,535,036 \$	8,050,736	\$ 10,585,772
Total liabilties	560,815	35,094	595,909
As at December 31, 2019			
Total assets	\$ 2,910,192 \$	10,755,202	\$ 13,665,394
Total liabilties	383,272	80,095	463,367

Note 20 - Related Party Transactions

Balances and transactions between the Company and its wholly owned and controlled subsidiaries have been eliminated on consolidation and are not disclosed in this note. Details of the transactions between the Company and other related parties are disclosed below:

	9 months ended September 30 2020	I	Year ended December 31 2019		
Key Employees (management)					
Salaries and benefits	\$ 185,040	\$	200,000		
Management fees to the CFO	41,666		200,046		
Fees paid to Directors	9,000		-		

These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Note 21 – Capital Management

The Company's objectives when managing capital are to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern and to maintain adequate levels of funding to support its ongoing operations and development such that it can continue to provide returns to shareholders and benefits for other stakeholders.

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 21 - Capital Management, continued

The capital structure of the Company consists of items included in shareholders' equity and debt, net of cash and cash equivalents. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the Company's underlying assets. In order to maintain or adjust its capital structure, the Company may issue new shares or seek additional debt financing to ensure that it has sufficient working capital to meet its short-term business requirements. There were no changes in the Company's approach to capital management during the periods ended September 30, 2020 or December 31, 2019.

Note 22 – Financial Instruments

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, trade and other receivables, investments, trade and other payables, short term debt payable, derivative liability, contingent consideration, loans receivable, and loans payable.

Fair value

The carrying values of cash and cash equivalents, trade and other receivables, and trade and other payables approximate their fair values due to the short-term nature of these instruments.

In evaluating fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange.

Fair value measurements of investments and loan receivable are as follows:

			Fair Value Measurements Using							
	(Carrying Amount		Level 1 Level 2		ng Amount Level 1 Lev			Level 3	
September, 2020										
Investments	\$	408,204	\$	48,204	\$	-	\$	360,000		
Loan receivable		727,925		-		727,925		-		
December 31, 2019										
Investments	\$	376,502	\$	16,502	\$	-	\$	360,000		

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

As at September 30, 2020 and December 31, 2019, the Company measured its investment in Sebastiani Ventures Corp. and Golden Ridge Resources Ltd., at Level 1 fair value.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

As at September 30, 2020, the Company measured its loan to Enhanced Pet Sciences Corp. at Level 2 fair value as there is no active market for this loan.

Notes to the Condensed Consolidated Interim Financial Statements

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019

(Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 22 – Financial Instruments, continued

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The investment in Enhanced Pet Sciences Corp. is measured at fair value, but as the investment is privately held and there is no quoted market price for its common shares, fair value is deemed to be best represented by the initial acquisition price of the investment.

There were no transfers between levels 1, 2 and 3 inputs during the period.

Risk Management

The Company is exposed to risks of varying degrees of significance from its use of financial instruments which could affect its ability to achieve its strategic objectives for growth and stakeholder returns. The principal risks to which the Company is exposed, and the actions taken to manage them, are described below.

Credit Risk

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is moderately exposed to credit risk from its cash and cash equivalents and trade and other receivables. The risk exposure is limited to their carrying amounts at the balance sheet date. The risk is mitigated by holding cash and cash equivalents with highly rated Canadian financial institutions. The Company does not invest in asset- backed deposits or investments and does not expect any credit losses. The Company periodically assesses the quality of its investments and is satisfied with the credit rating of the financial institutions and the investment grade of its guaranteed investment certificates. Trade and other receivables primarily consist of trade accounts receivable and Goods and Services Tax recoverable ("GST").

The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk, but has limited risk as the majority of sales are transacted with credit cards.

As at September 30, 2020 and December 31, 2019 all of the Company's trade receivables were current.

Interest Rate Risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. The Company has obtained primarily fixed rate debt which limits its exposure to interest rate fluctuations.

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to settle obligations and liabilities when due.

At September 30, 2020 the contractual obligations related to financial liabilities were as follows:

	Less than	1-5	
	1 year	Years	Total
Trade and other payables	\$ 170,451	\$ -	\$ 170,451
Loan payable and convertible debenture	-	448,033	448,033

Three and Nine Months Ended September 30, 2020 and Year Ended December 31, 2019 (Unaudited – Amounts reflected in thousands of Canadian dollars, except share and per share amounts)

Note 23 - Reclassification of Prior Period Presentation

Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

Note 24 – Subsequent Events

The outbreak of the Coronavirus Disease 2019, or COVID-19, has spread across the globe and is impacting worldwide economic activity. This global pandemic poses the risk that the Company or its clients, employees, contractors, suppliers, and other partners may be unable to conduct regular business activities for an indefinite period of time. While it is not possible at this time to estimate the impact that COVID-19 could have on the Company's business, the continued spread of COVID-19 and the measures taken by the federal, provincial and municipal governments to contain its impact could adversely impact the Company's business, financial condition or results of operations. The extent to which the COVID-19 outbreak impacts the Company's results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the spread of the virus and government actions.

At the October 29, 2020 board meeting the Directors of the Company voted to adopt the Amended and Restated Stock Option and Restricted Share Unit Plan (the Amended Plan). The Amended Plan now includes Restricted Share Units (RSUs) as a form of employee compensation. The Directors also approved 15,000,000 RSUs to be granted to executive management and directors, vesting over a two-year period. RSUs vest at current market value per share. In addition, 4,000,000 stock options were granted to employees vesting over a four-year period at an exercise price of \$0.02 per share. Share based compensation expense related to the options is approximately \$20,000 and will be recorded in Q4 2020.